benzyl 4-({3-[(tert-butoxycarbonyl)amino]propyl}amino)piperidine-1-carboxylate | 936129-65-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 4-({3-[(tert-butoxycarbonyl)amino]propyl}amino)piperidine-1-carboxylate
• 英文别名: Benzyl 4-[(3-{[(tert-butoxy)carbonyl]amino}propyl)amino]piperidine-1-carboxylate；benzyl 4-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propylamino]piperidine-1-carboxylate
• CAS: 936129-65-6
• 化学式: C₂₁H₃₃N₃O₄
• 分子量: 391.511
• InChiKey: VJBBZKXRUFDAQT-UHFFFAOYSA-N

物化性质

• 沸点：
  542.0±50.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  79.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  benzyl 4-({3-[(tert-butoxycarbonyl)amino]propyl}amino)piperidine-1-carboxylate 以91的产率得到Benzyl 4-[(3-aminopropyl)amino]piperidine-1-carboxylate dihydrochloride
  参考文献：
  名称：

  J. Med. Chem. 2010, 53, 3517-3531

  摘要：

  DOI：
• 作为产物：
  描述：

  1-Cbz-4-哌啶酮 、 N-叔丁氧羰基-1,3-丙二胺 在 溶剂黄146 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以98%的产率得到benzyl 4-({3-[(tert-butoxycarbonyl)amino]propyl}amino)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS
  [FR] COMPOSÉS AZA BICYCLIQUES EN TANT QU'AGONISTES DU RÉCEPTEUR MUSCARINIQUE M1.

  摘要：

  公开号：

  WO2015118342A8

文献信息

• Discovery of a Tetrahydropyrimidin-2(1<i>H</i>)-one Derivative (TAK-442) as a Potent, Selective, and Orally Active Factor Xa Inhibitor
  作者：Takuya Fujimoto、Yasuhiro Imaeda、Noriko Konishi、Katsuhiko Hiroe、Masaki Kawamura、Garret P. Textor、Kathleen Aertgeerts、Keiji Kubo

  DOI：10.1021/jm901699j

  日期：2010.5.13

  Coagulation enzyme factor Xa (FXa) is a particularly promising target for the development of new anticoagulant agents. We previously reported the imidazo[1,5-c]imidazol-3-one derivative 1 as a potent and orally active FXa inhibitor. However, it was found that 1 predominantly undergoes hydrolysis upon incubation with human liver microsomes, and the human specific metabolic pathway made it difficult to predict the human pharmacokinetics. To address this issue, our synthetic efforts were focused on modification of the imidazo[1,5-c]imidazol-3-one moiety of the active metabolite 3a, derived from 1, which resulted in the discovery of the tetrahydropyrimidin-2(1H)-one derivative 5k as a highly potent and selective FXa inhibitor. Compound 5k showed no detectable amide bond cleavage in human liver microsomes, exhibited a good pharmacokinetic profile in monkeys, and had a potent antithrombotic efficacy in a rabbit model without prolongation of bleeding time. Compound 5k is currently under clinical development with the code name TAK-442.
• Bioorg. Med. Chem. 2009, 17, 7993-8002
  作者：

  DOI：——

  日期：——
• BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：EP3102568A1

  公开（公告）日：2016-12-14
• US9670183B2
  申请人：——

  公开号：US9670183B2

  公开（公告）日：2017-06-06
• [EN] 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] 3-IMIDAZOLYL-INDOLES POUR TRAITER LES MALADIES PROLIFÉRATIVES
  申请人：NOVARTIS AG

  公开号：WO2012176123A1

  公开（公告）日：2012-12-27

  The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I), in which: R1, R2, R3 and R4 are as defined in the Summary of the Invention. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.